Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis makes competing bid for Zentiva

Sanofi-aventis has announced that it intends to make a bid of $1.7bn for the Czech generic drug manufacturer, Zentiva
Sanofi-aventis has announced that it intends to make a bid of $1.7bn for the Czech generic drug manufacturer, Zentiva, outbidding an earlier offer from Czech financial group PPF.

Paris-based sanofi-aventis already holds a 24.9 per cent share in Zentiva while PPF, together with Italian insurer Generali, owns 19.2 per cent. The offer from sanofi-avensis is 10.5 per cent higher than the initial bid from the Czech financial house.

The acquisition of Zentiva would give the French pharmaceutical company more than 180 generic medicines, an area of the market growing at twice the rate of patent-protected products.

Zentiva is a market leader in the Czech Republic, Turkey, Romania and Slovakia, with a growing presence in Poland, Russia, Bulgaria, the Ukraine and the Baltic countries. Sanofi-aventis is already established in many of these markets and says that acquiring control of the generics manufacturer "carries a strong strategic rationale."

18th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics